Hannah Joseph Hospital Limited FY26: A Neuroscience Hub With a Balance Sheet Holding Its Breath

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

Prices referenced are not live. Analysis uses CMP of ₹98.35 dated June 11, 2026.

1. At a Glance

Hannah Joseph Hospital ticked all the right boxes in FY26—a neuroscience-focused 150-bed facility in Madurai that grew sales 18.7% to ₹92 Cr, while net profit jumped 55% to ₹11.2 Cr. ROCE sits at 18%, the debt-to-equity ratio is 0.28, and the company just paid a ₹2 dividend.

But here’s the tension: the P/E of 20x trades below the peer median of 45.5x, which usually signals either a bargain or a reason why it’s cheap. The balance sheet held ₹43.2 Cr cash at March 2026, against a market cap of ₹223 Cr. Return on equity is 15%, not stellar for healthcare.

The company floated its IPO in January 2026 at ₹40 Cr raised. It’s now building a radiation oncology centre. The order is whether margin expansion and capex execution can sustain the momentum or if the multiple is cheap for a reason.

2. Introduction

Hannah Joseph Hospital Limited (HJHL) is a 150-bed tertiary care multi-specialty hospital based in Madurai, Tamil Nadu, incorporated in 2011. The facility operates 133 beds across six clinical floors and carries a dominant clinical focus on Neurosciences, Cardiac Sciences, Psychiatry, and Trauma care.

The company IPO’d on January 30, 2026, listing on the BSE SME platform (symbol: HANNAH). The issue was oversubscribed and raised ₹40 Cr in net proceeds, with stated uses for capex on the Radiation Oncology department and general corporate purposes. As of May 2026, the company had utilized ₹7.5 Cr of the IPO proceeds and held ₹342.7 Cr in fixed deposits for future construction.

The board approved FY26 audited results on May 29, 2026, recommending a ₹2 per share final dividend (20% on face value) for shareholder approval at the AGM. The auditor issued an unmodified opinion. Promoter holdings stand at 71.3%, with Dr. Mosesjoseph Arunkumar holding 69.2% directly.

3. Business Model: WTF Do They Even Do?

Hannah Joseph operates a one-facility, one-geography model—150 sanctioned beds (133 operational) in Madurai, focussed on specialist care, not mass-market bed churn.

Revenue mix by service type (FY25): Healthcare services comprise 74% of revenue (the bedside work). Pharmacy contributes 25.5% (selling medicines to inpatients and outpatients). Food and ancillaries round out the remainder. Within healthcare, in-patient stays generate 90.8% of revenue; outpatient visits contribute 9.2%.

The numbers that matter: FY25 saw 1,413 in-patient admissions and 7,487 outpatient visits. The average length of stay (ALOS) was 15 days. Average revenue per occupied bed (ARPOB) was ₹25,255 per day. Bed occupancy crept up to 42.5% from 37.2% the prior year.

The specialty strategy is deliberate. Neurosciences carries an academic seat—the company runs a Dr. N.B. Neurosurgery chair with 2 seats. Cardiac Sciences houses interventional capabilities. Psychiatry handles schizophrenia, bipolar, depression, substance abuse, child/adolescent cases, and dementia. Trauma spans orthopaedics, oral surgery. Support services include a radiology suite (MRI, CT, X-ray, ultrasound), ICU/ICCU, and pathology.

In January 2025, the company acquired 82 cents of land to establish a Radiation Oncology department—a pivotal move into cancer treatment and a diversification away from neuro and cardiac dominance. The IPO capital is earmarked for this build-out.

4. Financials Overview

Figures are consolidated, in ₹ crore.

FY26 results are on a Half-Yearly basis: Mar 2025 and Sep 2025 results were announced separately; Mar 2026 is the balancing figure. The latest complete quarterly window (Q4 Mar 2026) encompasses the full FY26 year-end.

Full-year FY26 (annual): Revenue: ₹92.05 Cr | EBITDA: ₹25.0 Cr (27% margin) | PAT: ₹11.18 Cr (12.2% margin) | EPS: ₹4.93 (annualized)

Business trajectory: Sales grew from ₹78 Cr (FY25) to ₹92 Cr (FY26), a 18.1% step. Operating profit (EBITDA) expanded from ₹21 Cr to ₹25 Cr. Net profit surged from ₹7.2 Cr to ₹11.2 Cr. The jump in PAT was disproportionate to sales growth—a 55% jump on an 18% revenue lift—which reflects both operational leverage and a lower tax burden (tax rate held at 30% vs. prior year).

From the management’s own mouth: The Board has made no forward guidance. The Concall transcript is not available in public domain. No management commentary on margins, capex timing, or admission targets.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market pays 20x earnings here versus a peer median of 45.5x. HJHL’s multiple sits at less than half the peer band, despite matching or